卜氟胺 | 338-83-0

• 物质功能分类: 有机原料 - 有机氟化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 卜氟胺
• 中文别名: 全氟胺；全氟三丙胺；FC-3283
• 英文名称: Perfluorotripropylamine
• 英文别名: 1,1,2,2,3,3,3-heptafluoro-N,N-bis(1,1,2,2,3,3,3-heptafluoropropyl)propan-1-amine；perfluoro-(tri-n-propylamine)；FC-3283；FTPA
• CAS: 338-83-0
• 化学式: C₉F₂₁N
• mdl: MFCD00042589
• 分子量: 521.072
• InChiKey: JAJLKEVKNDUJBG-UHFFFAOYSA-N

物化性质

• 熔点：
  -52 °C
• 沸点：
  125-135°C
• 密度：
  1.82
• 溶解度：
  DMSO（少许）、甲醇（少许）、水（少许）
• LogP：
  5.3-6.1
• 蒸汽压力：
  20 mm Hg @ 37 °C
• 折光率：
  Index of refraction: 1.279 @ 25 °C

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  22

ADMET

毒理性

• 解毒与急救

基本治疗：建立专利气道。如有必要，进行吸痰。观察呼吸不足的迹象，并在需要时辅助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，并在必要时进行治疗……。监测休克，并在必要时进行治疗……。预期癫痫发作，并在必要时进行治疗……。对于眼睛污染，立即用水冲洗眼睛。在转运过程中，用生理盐水连续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能吞咽、有强烈的干呕反射且不流口水，则用水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。在去污后，用干燥的无菌敷料覆盖皮肤烧伤……。/毒药A和B/

Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poison A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

高级治疗：对于无意识、严重肺水肿或呼吸停止的患者，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。监测心率和必要时治疗心律失常。 ... 开始静脉输液，使用D5W/SRP：“保持开放”，最低流量/。如果出现低血容量的迹象，使用乳酸钠林格氏液。注意液体过载的迹象。考虑使用药物治疗肺水肿。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象。用地西泮（安定）治疗癫痫。使用丙美卡因氢氯化物协助眼部冲洗。/毒药A和B/

Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in respiratory arrest. Positive pressure ventilation techniques with a bag valve mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poison A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

实验动物：急性暴露/使用大鼠的肝脏巨噬细胞系统，通过磁测量法检查了静脉注射各种全氟化学品（乳化全氟癸炔（C10F18）、全氟辛烷（C8F17Br）和Fluosol-DA（相当于70%全氟癸炔和30%全氟三丙胺的20%乳液，C9F21N））后的细胞变化。在给予高剂量后，所有全氟化学品都导致了细胞骨架的改变。这种改变，表现为铁磁性氧化铁颗粒的松弛期延迟，在给予Fluosol-DA后最为明显。

/LABORATORY ANIMALS: Acute Exposure/ Using the hepatic macrophage system of the rat, cell alteration was examined by magnetometry after intravenous application of various perfluorochemicals (emulsified perfluorodecalin (C10F18), perfluorooctane (C8F17Br) and Fluosol-DA (corresponding to a 20% emulsion of 70% perfluorodecalin and 30% perfluorotripropylamine, C9F21N)). After administration of high doses, all perfluorochemicals led to cytoskeleton alteration. This alteration, expressed as retardation of the relaxation period of ferromagnetic iron oxide particles, was most pronounced after administration of Fluosol-DA.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

实验室动物：急性暴露/研究了全氟碳化合物（PFC）乳剂（7份全氟癸烷和3份全氟三丙胺，4.4克PFC/千克体重）对器官功能的影响。尽管在PFC给药后仅12小时脾脏就达到了PFC的最大储存量，但肝脏直到2天后才达到PFC含量的最大值。体重的增加也有所不同：在第4天脾脏达到最大值，在第8天肝脏达到最大值。吲哚菁绿（ICG）清除率略有下降，在12小时和24小时后统计学上有显著差异。作为网状内皮系统（RES）功能指标的胶体碳清除率在PFC给药后立即下降到对照组值的一半以下；在完全恢复后，出现了第二次下降，持续到PFC给药后的第4天。C 48/80预处理或以递增剂量的E. coli内毒素预处理可以在很大程度上消除PFC负荷对碳清除率的抑制作用。血清转氨酶增加到约为对照组的两倍，但在第二天恢复正常，之后也保持正常。碱性磷酸酶显示出2.5倍的增加，但在第二天后恢复到对照组水平。结论是，尽管没有发生严重的肝脏功能紊乱，但如果RES的能力下降，如果没有通过激活RES来补偿，那么在同时出现的感染防御中，这可能会成为一个严重的问题。/全氟化学乳剂/

/LABORATORY ANIMALS: Acute Exposure/ The effect of an emulsion of perfluorochemicals (PFC) (7 parts perfluorodecalin and 3 parts perfluorotripropylamine, 4.4 g PFC/kg bw) on organ function was determined. Whereas maximal storage of PFC was reached in the spleen as early as 12 hr after PFC administration, the liver attained a maximal PFC content only after 2 days. The increase in weight also differed: a maximum occurred in the spleen on the 4th day, in the liver on the 8th day. Indocyanine green (ICG) clearance showed a small decrease, statistically significant after 12 and 24 hr. Colloidal carbon clearance, used as a measure of the function of the reticuloendothelial system (RES) decreased instantly after PFC to less than half the control value; after full recovery a second decrease was seen which lasted till the 4th day after PFC. Pretreatment with C 48/80 or with increasing doses of E. coli endotoxin could largely obviate the depressive effect of PFC-loading on carbon clearance. Serum transaminases increased to about twice the control levels but were normal by the 2nd day, and thereafter. Alkaline phosphatase showed a 2.5 fold increase but returned to control level after the 2nd day. It is concluded that while a severe disturbance of liver function did not occur, the reduction in the capacity of the RES can become a serious factor in the defense against a simultaneously appearing infection if not compensated by activating the RES. /Perfluoro chemical emulsion/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

实验室动物：急性暴露/由于对氟碳化合物改善心肌缺血的机制存在不确定性，因此研究了氟碳乳剂、全氟癸烷和全氟三丙胺（Fluosol-DA 20% TM）在有无100% O2吸入的情况下，对麻醉犬的心脏血流动力学和能量代谢的影响。通过在氟碳化合物输注前和输注后（40 ml/kg）测量左心室（LV）心肌内部分氧压（PmO2），并将其与另一组接受体积扩张剂右旋糖酐（36 ml/kg）的狗的测量值进行比较。然后两组狗都使用100% O2进行通气，并重复测量。在接收氟碳化合物的11只动物中，出现了与体积扩张相容的左房压、LV心肌血流量和LV心肌氧消耗（MVO2）的增加。在100% O2之后，LV MVO2降低到控制值，而PmO2增加到127 +/- 48 mm Hg（p<0.001）。在整个研究过程中，心率、动脉压或LV压力的一阶导数（dP/dt）没有显著变化。在接受右旋糖酐治疗的10只狗中，心率和dP/dt没有变化，但动脉和左房压力在右旋糖酐输注后升高，并在100% O2吸入后保持升高。LV MVO2随着体积扩张而增加，并在100% O2后保持增加。100% O2后的PmO2（66 +/- 18 mm Hg）低于（p<0.02）氟碳化合物处理过的狗在O2吸入后的值。

/LABORATORY ANIMALS: Acute Exposure/ Because of uncertainty about the mechanism by which fluorocarbons ameliorate myocardial ischemia, the effects of a fluorocarbon emulsion, perfluorodecalin and perfluorotripropylamine (Fluosol-DA 20% TM) with and without 100% O2 inhalation, on cardiac hemodynamics and energetics were studied in the anesthetized dog. Left ventricular (LV) intramural partial pressure of oxygen (PmO2) was measured by before and after iv infusion of Fluosol-DA 20% (40 ml/kg), and was compared with measurements made in another group of dogs receiving the volume expander dextran (36 ml/kg). Both groups of dogs were then ventilated with 100% O2 and repeat measurements were performed. In the 11 animals receiving fluorocarbons, there were increases in left atrial pressure, LV myocardial blood flow, and LV myocardial O2 consumption (MVO2) compatible with volume expansion. After 100% O2, LV MVO2 decreased to control values, while PmO2 increased to 127 +/- 48 mm Hg (p<0.001). There were no significant changes in heart rate, arterial pressure or first derivative of LV pressure (dP/dt) during the study. In 10 dogs treated with dextran there was no change in heart rate or dP/dt, but arterial and left atrial pressures were higher after dextran infusion and remained elevated after 100% O2 inhalation. LV MVO2 increased with volume expansion, and remained increased after 100% O2. PmO2 (66 +/- 18 mm Hg) after 100% O2 was lower (p<0.02) than in the fluorocarbon-treated dogs after O2 inhalation.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

研究了在大鼠循环系统中，单次注射三种不同剂量的全氟碳化合物（PFC）后其浓度下降的情况。使用的剂量相当于每千克体重4.4、10和14克的全氟碳乳剂Fluosol-DA，该乳剂由7份全氟癸烷（FDC）和3份全氟三丙胺（FTPA）组成。这也使得可以测试循环系统中剩余乳剂的组成以及肝脏中发现的乳剂组成。在最高剂量下，两天后循环系统中的半衰期从34.0 +/- 0.7降低到17.1 +/- 4.3小时。与此同时，血液中乳剂的组成发生了变化，有利于FTPA的比例。到第四天，FTPA的比例从28.3 +/- 1.4增加到54.4 +/- 8.1%。而在肝细胞中，PFC滴可能被分解，从其表面活性剂层中释放出来，并根据其单个成分进行处理，对于血液中的PFC，应该假设其组成不变。这两个结果，即半衰期的减少和循环乳剂组成的变化，最好解释为乳化剂薄膜的收缩和不稳定，这表明有必要开发一种更优秀的表面活性剂。/Fluosol-DA/

The decline of the concentration of perfluorochemicals (PFC) after a single injection of three different doses was studied in the circulation of rats. The doses used amounted to 4.4, 10 and 14 g/kg body weight of Fluosol-DA, an emulsion of 7 parts of perfluorodecalin (FDC) and 3 parts of perfluorotripropylamine (FTPA). This also allowed testing of the composition of the emulsion remaining in the circulation and of that found in the liver. After two days a decrease of the half life from 34.0 +/- 0.7 to 17.1 +/- 4.3 h was found within the circulation at the highest dose. At the same time a change in the composition of the emulsion in the blood stream occurred, favouring the fraction of FTPA. FTPA increased from 28.3 +/- 1.4 to 54.4 +/- 8.1% on the fourth day. Whereas in the cells of the liver PFC droplets may be broken up, freed from their surfactant layer and handled according to their individual components, for PFC in the blood stream an unchanged composition should be assumed. Both results, the decreasing half life and the change in composition of the circulating emulsion may best be explained by a shrinking and instability of the emulgator film, showing the necessity for development of a superior surfactant. /Fluosol-DA/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

全氟碳化合物（PFC）乳剂（7份全氟癸烷和3份全氟三丙胺，4.4克PFC/千克体重）对器官功能的影响已经确定。尽管在PFC给药后仅12小时脾脏就达到了PFC的最大储存量，但肝脏在2天后才达到PFC含量的最大值。

The effect of an emulsion of perfluorochemicals (PFC) (7 parts perfluorodecalin and 3 parts perfluorotripropylamine, 4.4 g PFC/kg body weight) on organ function was determined. Whereas maximal storage of PFC was reached in the spleen as early as 12 h after PFC administration, the liver attained a maximal PFC content only after 2 days.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• TSCA：
  T
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2921199090
• 安全说明：
  S26,S36
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险品运输编号：
  2735
• 危险性描述：
  H314,H319
• 储存条件：
  本品应密封保存在阴凉处。

制备方法与用途

生物活性

Perfluamine（全氟三丙胺）是一种疏水性载体流体，用于液滴聚合物微流控器件的表面改性。它还具有血液代用品的作用。

化学性质

无色、无臭、无毒的不燃、惰性液体，在37℃时对O2的溶解度为45.3%（体积），对CO2的溶解度为166%（体积）。

用途

Perfluamine用作仪器仪表的抗腐蚀传动液和介电绝缘液，也可作为电子元件、器件检漏液。

反应信息

• 作为反应物：
  描述：

  卜氟胺 以82%的产率得到difluoromethylene-heptafluoropropyl-amine
  参考文献：
  名称：

  US2643267

  摘要：

  公开号：
• 作为产物：
  描述：

  三正丙胺 在 fluorine 、 sodium fluoride 作用下， 以 1,1,2-三氯三氟乙烷（CFC-113） 为溶剂， 反应 5.0h， 以72.5%的产率得到卜氟胺
  参考文献：
  名称：

  全氟化叔烷基胺的高效高产合成

  摘要：

  我们希望报道通过直接氟化从其烃类似物高产率合成全氟化叔胺的方法。从某些叔胺获得了高达70％的高纯度收率。该技术可能会发展成为一种生产全氟胺的新通用方法。

  DOI：

  10.1016/s0022-1139(03)00146-5
• 作为试剂：
  描述：

  、 尿素 在 三乙胺 作用下， 以 卜氟胺 为溶剂， 反应 1.5h， 以91%的产率得到
  参考文献：
  名称：

  [EN] FLUOROORGANIC COMPOUNDS AND ANTI-FOULING TREATMENTS
  [FR] COMPOSES ORGANIQUES FLUORES ET TRAITEMENTS ANTISALISSURE

  摘要：

  公开号：

  WO2005123646A3

文献信息

• MEDICINAL PREPARATION
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP1787661A1

  公开（公告）日：2007-05-23

  A pharmaceutical preparation has a ligand structure specifically recognizing a target site and an amphiphilic compound having a hydrophobic or amphiphilic group. The pharmaceutical preparation employs an amphiphilic compound of specific structure obtained by introducing a chained hydrophilic group with an appropriate flexibility, and thus becomes a fine particle suited for drug targeting. The pharmaceutical preparation is expected to give a prolonged pharmacological effect. A particulate preparation exhibiting a remarkable site targeting property can be formed. Further, according to the selection of matrix forming material, the drug releasing property can be controlled.

  一种药物制剂具有特异性识别靶位点的配体结构和具有疏水或两性亲和性基团的两性化合物。该药物制剂采用通过引入具有适当柔韧性的链状亲水基团获得的特定结构的两性化合物，因此成为适用于药物靶向的细颗粒。 预计该药物制剂将产生持久的药理效应。可以形成具有显著靶向性能的颗粒制剂。此外，根据基质形成材料的选择，可以控制药物释放性能。
• NANOEMULSIONS AND USE THEREOF AS CONTRAST AGENTS
  申请人：GUERBET

  公开号：US20140234223A1

  公开（公告）日：2014-08-21

  The invention relates to an oil-in-water nanoemulsion for MRI, including: an aqueous phase, a fluorinated phase including at least one fluorinated oil, a surfactant at the interface between the aqueous and fluorinated phases, the surfactant comprising: at least one amphiphilic targeting ligand, at least one amphiphilic lipid, and at least one diblock or triblock fluorophilic compound, as well as to the use thereof as a contrast agent.

  这项发明涉及一种用于磁共振成像的油包水纳米乳液，包括： 水相， 含有至少一种氟化油的氟化相， 位于水相和氟化相之间的表面活性剂，所述表面活性剂包括： 至少一种两性靶向配体， 至少一种两性脂质，以及 至少一种二嵌段或三嵌段亲氟化合物， 以及将其用作对比剂的用途。
• Synthesis of perfluorochemicals for use as blood substitutes, part II: electrochemical fluorination of partly fluorinated compounds
  作者：Taizo Ono、Yoshihisa Inoue、Chikara Fukaya、Yoshio Arakawa、Youichiro Naito、Kazumasa Yokoyama、Kouichi Yamanouchi、Yoshiro Kobayashi

  DOI：10.1016/s0022-1139(00)81314-7

  日期：1985.3

  Electrochemical fluorination of 2-methoxy-1,1,1-trifluoro-2-(F-methyl) octane gave the corresponding perfluorinated ether in 27% yield, along with cyclic by-products in 9%. A mixture of partly fluorinated tertiary amines, consisting of 1-dipropylamino-F-1-propene and 1-dipropylamino-2-hydryl-F-propane, did not afford a superior yield of tri(F-propyl)amine compared to the unfluorinated tripropylamine

  2-甲氧基-1,1,1-三氟-2-（F-甲基）辛烷的电化学氟化以27％的收率得到相应的全氟化醚，以及9％的环状副产物。由1-二丙基氨基-F-1-丙烯和1-二丙基氨基-2-氢-F-丙烷组成的部分氟化叔胺的混合物与未氟化的三（F-丙基）胺相比，不能提供更高的收率。三丙胺。将1-二乙基氨基-2-（F-甲基）-F-1-戊烯与1-二（F-乙基）氨基-2-氢-2-基氟化，以相当好的收率得到相应的F-叔胺。 （F-甲基）-F-戊烷及其片段化产物。研究表明，用F-甲基封端醚的α-碳原子似乎可以减少断裂，从而导致未重组产物的收率很高。然而，
• [EN] TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS DE DÉRIVÉS DE TRÉPROSTINIL ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CORSAIR PHARMA INC

  公开号：WO2016010538A1

  公开（公告）日：2016-01-21

  Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

  由I、II、III和IV式代表的化合物包括曲前列素和前列环素类似物的前药。用途包括治疗肺动脉高压（PH）或肺动脉高压（PAH）。这些化合物的结构可以根据适当的治疗剂量调整以适应特定的应用。可以使用经皮应用。
• [EN] PRODRUGS OF TREPROSTINIL<br/>[FR] PROMÉDICAMENTS DE TRÉPROSTINIL
  申请人：THERATROPHIX LLC

  公开号：WO2014110491A1

  公开（公告）日：2014-07-17

  Prodrugs of treprostinil are provided which can be used in the treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

  Treprostinil的前药提供了，可用于治疗肺动脉高压（PH）或肺动脉高压（PAH）。这些化合物的结构可以根据适当的治疗剂量适应特定应用。可以使用经皮应用。